PL EN


2012 | 3 | 468-473
Article title

Nowe możliwości leczenia powikłań ocznych cukrzycy

Content
Title variants
Languages of publication
PL
Abstracts
Contributors
References
  • Http://www.who.int/mediacentre/factsheets/fs312/en/, Fact sheet N°312 August 2011.
  • Kański J. Okulistyka kliniczna. Wrocław: Górnicki Wydawnictwo Medyczne; 2005: 439−455.
  • Shah AM, Bressler NM, Jampol LM, et al. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 2011; 152(3): 332−339. Epub 2011 Jul 13.
  • Stefánsson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scan 2001; 79(5): 435−440.
  • Muraly P, Limbad P, Srinivasan K, et al. Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparitive study. Retina 2011; 31(7):1359−1365.
  • Luttrull JK, Musch DC, Spink CA. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye (Lond) 2008; 22(5): 607−612.
  • Manaviat MR, Rashidi M, Afkhami-Ardekani M, et al. Effect of pan retinal photocoagulation on the serum levels of vascular endothelial growth factor in diabetic patients. Int Ophthalmol 2011; 31(4): 271−275. Epub 2011 Jun
  • ETDRS Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94: 761–774.
  • Takatsuna Y, Yamamoto S, Nakamura Y, et al. Japanese long-term therapeutic efficacy of the subthreshold micropulse diode laser photocoagulation for diabetic macular edema. Jap J Ophthalmol 2011; 55(4): 365−369. Epub 2011 Jun 7.
  • Grant MB, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investigat Drugs 2004; 13: 1275–129
  • Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study):A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diab Care 2010; 33: 2399–2405.
  • Ozturk BT, Kerimoglu H, Bozkurt B, et al. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocuar Pharmacol Therapeut 2011; 27: 373–377.
  • Bandello F, De Benedetto U, Knutsson KA, et al. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 2011; 5: 1303−1308. Epub 2011 Sep 14.
  • Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina 2011; 31(4): 662−668.
  • Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. CATT Research Group. New Engl J Med 2011; 364(20): 1897−1908. Epub 2011 Apr 28.
  • Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 2011; 89(7): 567−572. Doi: 10.1111/j.1755-3768.201 02184.x. Epub 2011 Jul 5.
  • Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Diabetic Retinopathy Clinical Research Network, Retina 2011; 31(6): 1009−1027.
  • Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615–625.
  • Elman MJ, Bressler NM, Qin H, et al. Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.Ophthalmology 2011; 118(4): 609−614.
  • Stewart EA, Samaranayake GJ, Browning AC, et al. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments. Exp Eye Res 2011; 93(5): 761−766. Epub 2011 Sep 28.
  • Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefe’s Arch Clin Exp Ophthalmol 2011; 249(7): 997−1008. Epub 2011 Jan 18.
  • Yang SJ, Yoon SY, Kim JG, et al. Transconjunctival sutureless vitrectomy for the treatment of vitreoretinal complications in patients with diabetes mellitus. Ophthal Surg Lasers Imaging 2009; 40(5): 461−466. Doi: 10.3928/15428877-20090901-04
  • Zhao LQ, Zhu H, Zhao PQ, et al. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95(9):1216−1222. Epub 2011 Jan 27.
  • Naser H, Koss MJ, Singh P, et al. Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone. Klin Monatsblatt Augenheilkunde 2011; 228(10): 910−914. Epub 2011 Oct 13.
  • Nadal J, Capella MJ. Treatment of proliferative diabetic retinopathy using viscosurgery with vital dye. Arch Ophthalmol- Chic 2011; 129(10): 1358−1360.
  • Wolf A, von Jagow B, Ulbig M, et al. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma.Ophthalmologica 2011; 226(2): 51−56. Epub 2011 May 5.
  • Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefe’s Arch Clin Exp Ophthalmol 2010; 248(11): 1601−1609. Epub 2010 Jun 4.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.desklight-60e97a52-9edb-48bf-ae43-c40d3bc098bc
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.